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Background: Genetic variants of endothelial nitric oxide synthase (eNOS) could influence individual
susceptibility to coronary artery disease.
Objective: To assess whether Glu298!Asp polymorphism of the eNOS gene is associated with the
occurrence and severity of angiographically defined coronary artery disease in the Italian population.
Methods: Polymerase chain reaction/restriction fragment length polymorphism analysis was done to
detect the Glu298!Asp variant of the eNOS gene in 201 patients with coronary artery disease and 114
controls. The severity of coronary artery disease was expressed by the number of affected vessels and
by the Duke scoring system.
Results: The frequencies of the eNOS Glu/Glu, Glu/Asp, and Asp/Asp genotypes in the coronary
artery disease group were significantly different from those of controls (45.3%, 38.8%, and 15.9% v
42.1%, 51.8%, and 6.1%, respectively; "2 = 8.589, p = 0.0136). In comparison with subjects who
had a Glu298 allele in the eNOS gene, the risk of coronary artery disease was increased among Asp/
Asp carriers (odds ratio 2.9, 95% confidence interval 1.2 to 6.8, p = 0.01) and was independent of
the other common risk factors (p = 0.04). There was a significant association between the eNOS
Glu298!Asp variant and both the number of stenosed vessels (mean (SEM), 2.3 (0.1) for Asp/Asp v 1.9
(0.1) and 1.8 (0.1) for Glu/Glu and Glu/Asp, respectively; p = 0.01) and the Duke score (56.1 (3.1)
for Asp/Asp v 46.7 (2.0) and 46.1 (1.9) for Glu/Glu and Glu/Asp, respectively; p = 0.02).
Conclusions: Glu298!Asp polymorphism of the eNOS gene appears to be associated with the pres-
ence, extent, and severity of angiographically assessed coronary artery disease.
Epidemiological studies indicate that hyperlipidaemia,hypertension, cigarette smoking, diabetes, and obesityare risk factors for coronary artery disease.1–3 Control of
these environmental risk factors has, however, been ineffec-
tive in completely predicting development of the atheroscle-
rotic process, suggesting that specific genetic predisposition
should be taken into account as well.4 5
Vascular endothelium modulates blood vessel wall homeos-
tasis through the production of factors regulating vessel tone,
coagulation state, cell growth, cell death, and leucocyte
trafficking.6 One of the most important endothelial cell prod-
ucts is nitric oxide (NO), which is synthesised from L-arginine
by the enzyme endothelial nitric oxide synthase (eNOS).7 NO
plays a key role in the relaxation of vascular smooth muscle,
inhibits platelet and leucocyte adhesion to the endothelium,
reduces vascular smooth muscle cell migration and prolifera-
tion, and limits the oxidation of atherogenic low density
lipoproteins.8 Moreover, it has been shown that eNOS
inhibition accelerates atherosclerosis in animal models, and
that abnormalities of the endothelial NO pathway are present
in humans with atherosclerosis.9 10 This evidence suggests that
NOmay inhibit several key steps in the atherosclerotic process
and that an alteration of NO production within the vascular
endothelium could contribute to the pathogenesis of athero-
sclerosis. Thus eNOS could be a candidate gene for atheroscle-
rosis.
Several polymorphisms have been identified in the eNOS
gene, among which is one located in exon 7 (G984T) which
modifies its coding sequence (Glu298!Asp). Associations
between this variant and coronary spasm, coronary artery
disease, and acute myocardial infarction have been reported,
but data on its relation with disease severity are lacking.11 12 In
this paper, we describe the associations between the
Glu298!Asp polymorphism of the eNOS gene and the
occurrence and severity of angiographically defined coronary
artery disease in the Italian population.
METHODS
Study population
We studied 201 patients consecutively admitted to our institu-
tion with angiographically proven coronary artery disease
(more than 50% stenosis affecting at least one vessel) and 114
control subjects recruited from patients admitted for valve
replacement, in whom angiographic examination excluded
the presence of coronary artery disease. All the patients and
controls were interviewed and data on smoking habits, hyper-
tension, diabetes, dyslipidaemia, and family history of coron-
ary artery disease were recorded. Informed consent was
obtained from all patients and controls, as required by our
ethics committee.
For coronary risk factors, the following definitions were
used: subjects were defined as hypertensive if their blood
pressure was > 140/90 mm Hg or if they were receiving any
antihypertensive treatment; those with a history of diabetes or
who were receiving any antidiabetic drugs were considered to
be diabetic; those with a total plasma cholesterol concentra-
tion of > 5.70 mmol/l or a triglyceride concentration of
> 2.26 mmol/l, or who were receiving lipid lowering drugs,
were considered dyslipidaemic. Smoking history was coded as
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never, ex (for least six months), and current. A positive family
history was the presence of a first degree relative with coron-
ary artery disease at the age of < 55 years for men and < 65
years for women.
Angiographic study
All patients and controls underwent coronary angiography.
Coronary stenosis was considered significant in the presence
of a luminal diameter narrowing of > 50% of at least one epi-
cardial coronary artery. The severity of coronary artery disease
was expressed by the number of affected vessels (one, two, or
three vessel disease) and also by means of the Duke scoring
system13—a prognostic index that includes the number of dis-
eased major vessels, the presence of left main coronary artery
disease, the percentage narrowing of the major vessels, and
involvement of the left anterior descending coronary artery,
particularly when the proximal segment shows severe stenosis
(> 95%). The Duke score ranges from 0–100 (0 = no disease,
100 = the most severe disease).
Analysis of Glu298! Asp polymorphism on exon 7 of
eNOS gene
Genomic DNA was extracted from samples of whole blood by
standard methods.14 The coding sequence variant was a G!T
substitution at position 894 in exon 7 which determines the
Glu to Asp amino acid substitution (in codon 298) in the
mature eNOS protein. According to previously described pro-
cedure, genotyping of all subjects was performed by poly-
merase chain reaction amplification of exon 7 with the
primers 5#-CATGAGGCTCAGCCCCAGAAC-3# (sense) and 5#-
AGTCAATCCCTTTGGTGCTCAC-3# (antisense) followed by
MboI restriction enzyme digestion for 16 hours at 37°C.12 In the
presence of a T at nucleotide 894 which corresponds to Asp
298, the 206 base pair (bp) polymerase chain reaction product
is cleaved into two fragments of 119 and 87 bp. The products
of the digestion process were highlighted by electrophoresis
on a 1.5% agarose gel.
Statistical analysis
All statistical analyses were conducted with the Statview sta-
tistical package, version 5.0.1 (SAS Institute). Data are
expressed as mean (SEM). Differences between the means of
the two continuous variables were evaluated by Student’s t
test. Differences in non-continuous variables, genotype distri-
bution, and the Hardy–Weinberg equilibriumwere tested by "2
analysis. One way analysis of variance was used to analyse the
relations between genotypes and the general characteristics
and severity of coronary artery disease, in terms of the
number of diseased vessels and the Duke score. Logistic
regression analysis was used to assess the independent effect
of each risk factor on the occurrence of coronary artery
disease. A probability value of p < 0.05 was considered to be
significant.
RESULTS
Comparison of the two study groups
Demographic and clinical characteristics of patients and con-
trols were given in table 1. The prevalence of atherogenic risk
factors (including age, sex, hypertension, diabetes, cigarette
smoking, dyslipidaemia, and a family history of coronary
artery disease) was significantly higher in the patient group.
Distribution of the Glu298!Asp polymorphism of the
eNOS gene
Although the distribution of genotypes in both coronary
artery disease cases and controls satisfied the Hardy–
Weinberg equilibrium, the Glu298!Asp polymorphism in exon
7 of the eNOS gene was significantly associated with the pres-
ence of coronary artery disease in our patients (table 2). The
proportion of Asp298 homozygotes was 15.9% in the coronary
artery disease cases and 6.1% in control subjects ("2 = 8.589,
p = 0.0136).
In comparison with Glu298 homozygotes, the odds ratio (OR)
for coronary artery disease associated with the Asp/Asp geno-
type was 2.4 (table 3). Because Glu/Asp carriers were not at
Table 1 Demographic and clinical characteristics of
coronary artery disease cases and controls
CAD cases
(n=201)
Controls
(n=114) p Value
Age (years) (mean (SEM)) 59.8 (0.7) 56.7 (1.2) 0.02
Male sex 179 (89.0) 56 (49.1) <0.0001
Hypertension 123 (61.2) 32 (28.1) <0.0001
Diabetes 44 (21.9) 5 (4.4) <0.0001
Dyslipidaemia 138 (68.7) 23 (20.2) <0.0001
Smoking <0.0001
Non-smokers 77 (38.3) 75 (65.8)
Ex-smokers 91 (45.3) 25 (21.9)
Current smokers 33 (16.4) 14 (12.3)
Family history of CAD 89 (44.3) 28 (24.6) 0.0005
Number of diseased vessels
One vessel 73 –
Two vessels 65 –
Three vessels 63 –
Values are n (%) unless stated.
CAD, coronary artery disease.
Table 2 Genotype frequencies of Glu298!Asp
polymorphism in angiographically defined coronary
artery disease cases and controls
Glu/Glu Glu/Asp Asp/Asp Total
CAD cases 91 (45.3) 78 (38.8) 32 (15.9) 201
Controls 48 (42.1) 59 (51.8) 7 (6.1) 114
Values are n (%).
"2=8.589, p=0.0136 for genotype.
CAD, coronary artery disease.
Table 3 Odds ratio for coronary artery disease
among individuals heterozygous or homozygous for
the Asp298 variant
Genotype
Reference
group Odds ratio (95% CI) p Value
Asp/Asp Glu/Glu 2.4 (1 to 5.9) 0.03
Asp/Asp Glu/Glu +
Glu/Asp
2.9 (1.2 to 6.8) 0.01
CI, confidence interval.
Table 4 Relative risks of coronart artery disease by
coronary risk factors and by Glu298!Asp
polymorphism of the eNOS gene
Risk factor Relative risk (95% CI) p Value
Age 1 (0.9 to 1.0) 0.09
Male sex 7.6 (3.4 to 16.6) <0.0001
Smoking 1.4 (0.5 to 3.9) 0.48
Hypertension 2.9 (1.4 to 5.8) <0.01
Diabetes 10.6 (3.1 to 36.5) <0.0001
Dyslipidaemia 8.3 (4.1 to 16.6) <0.0001
Family history of CAD 2.2 (1.1 to 4.6) 0.03
Asp/Asp v Glu/Glu and
Glu/Asp genotypes
2.9 (1 to 8.8) 0.04
CAD, coronary artery disease; CI, confidence interval.
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increased risk of coronary artery disease (OR 0.66, 95% confi-
dence interval 0.4 to 1.1), the odds ratios associated with the
Asp/Asp genotype were therefore computed with Glu/Glu +
Glu/Asp considered as the reference group. As shown in table
3, in comparison with individuals homozygous and hetero-
zygous for Glu298, the odds ratio for coronary artery disease
among Asp/Asp carries was 2.9. Multivariate analysis showed
that the Asp/Asp genotype was an independent risk factor for
coronary artery disease (table 4).
Glu298!Asp polymorphism of the eNOS gene and
severity of coronary artery disease
The relations between several variables and Glu298!Asp geno-
type were studied in coronary artery disease patients (table 5).
We did not find any association between the genotype and
hypertension, dyslipidaemia, diabetes, smoking status, or
family history of coronary artery disease.
We found a significant association between the Glu298!Asp
variant of the eNOS gene and the severity of the disease in
terms of the number of stenosed vessels. eNOS Glu298!Asp
polymorphism was also associated with the extent and the
severity of coronary artery disease evaluated by the Duke
scoring system (mean (SEM): 56.1 (3.1) for Asp/Asp, 46.7
(2.0) for Glu/Asp, and 46.1 (1.9) for Glu/Glu; p = 0.02) (fig 1).
DISCUSSION
We report the association between the common Glu298!Asp
polymorphism of the eNOS gene and the occurrence of coron-
ary artery disease in the Italian population. We found an
excess of homozygosity for the Asp298 variant among coronary
artery disease cases compared with controls, and the risk of
developing coronary artery disease was about threefold higher
for Asp298 homozygotes than in persons with a Glu298 allele in
the eNOS gene. Multivariate analysis showed that this associ-
ation was independent of other factors related to coronary
artery disease risk. Our study provides the first evidence for an
association between Glu298!Asp polymorphism and the
extent and severity of coronary artery disease.
There was the expected clustering of coronary artery
disease risk factors among cases. However, we did not detect
an association between the Glu298!Asp polymorphism and
any of these possibly confounding variables.
Glu298!Asp polymorphism of the eNOS gene and risk
of atherosclerosis related disease
Up to now, Glu298!Asp polymorphism of the eNOS gene has
been linked to an increased risk of stroke, coronary
atherosclerosis, and acute myocardial infarction.15 16 Previous
studies from Japan and the UK have already suggested a role
for Glu298!Asp polymorphism in the development of coronary
atherosclerosis, with the excess risk being confined to Asp298
homozygosity,12 17 as in our study. These studies, however, also
showed that the genotype frequency of Glu298!Asp polymor-
phism can vary substantially among different populations. For
example, while in the Japanese population this polymorphism
could only explain a small part of the genetic susceptibility to
acute myocardial infarction, as the Asp/Asp genotype was
present in only five of 226 patients (2.2%),17 in the UK the
Asp/Asp genotype was found in 107 of 298 patients (35%) and
in 45 of 249 patients (18.1%) with coronary artery disease and
acute myocardial infarction, respectively.12 Our genotype
frequencies in both cases and controls were in agreement with
those recently reported by Lembo and colleagues among Ital-
ian subjects who had atherosclerotic plaques on their carotid
arteries and control subjects without carotid plaques.15 In that
study, Asp298 homozygosity was an independent risk factor for
the development of carotid plaques, but no association was
found between Glu298!Asp polymorphism of the eNOS gene
and the degree of involvement of the various segments of the
carotid arteries. Nevertheless, it is important to emphasise
that some groups have failed to find any relation between the
Asp298 variant and the risk of atherosclerosis.18–21 Elbaz and col-
leagues even found a significant association between the Glu/
Glu genotype and the risk of brain infarction.21
Functional significance of the Glu298!Asp
polymorphism of the eNOS gene
The fact that in our study the risk for coronary artery disease
was confined to Asp298 homozygotes suggested that homozy-
gosity for aspartic acid in position 298 could produce a reduc-
tion in the amount or enzymatic activity of eNOS. If the Asp298
variant of eNOS leads to altered NO synthesis, this could pro-
vide a mechanism for both its increased prevalence among
patients with coronary artery disease and its association with
the extent and severity of the disease. Several experimental
studies have in fact shown that a reduction in the endothelial
Table 5 General and clinical characteristics of patients in each Glu298!Asp
genotype
Variable
Glu298!Asp genotype
p Value
Glu/Glu
(n=91)
Glu/Asp
(n=78)
Asp/Asp
(n=32)
Age (years) (mean (SEM)) 60.0 (1.0) 59.9 (1.1) 58.5 (1.7) 0.74
Sex (% male) 90.1 85.9 93.7 0.44
Non-smokers (%) 34.4 37.7 34.4 0.87
Ex-smokers (%) 50 42.8 50
Current smokers (%) 15.6 19.5 15.6
Hypertension (%) 63.7 62.3 51.6 0.47
Diabetes (%) 22 24.7 16.1 0.62
Dyslipidaemia (%) 67 72.4 64.5 0.65
Family history of CAD (%) 46.1 44.2 40.6 0.86
Number of vessels involved (mean (SEM)) 1.9 (0.1) 1.8 (0.1) 2.3 (0.1) 0.01
CAD, coronary artery disease.
Figure 1 Glu298!Asp polymorphism of the eNOS gene and the
severity of coronary artery disease assessed by the Duke scoring
system.
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production of NO appears to be critical for the evolution, pro-
gression, and clinical manifestations of the atherosclerotic
process.22 23 It is noteworthy that in our study an association
was observed between the Glu298!Asp polymorphism and
both the number of diseased vessels and the Duke scoring
system—a prognostic index that also includes the percentage
narrowing of themajor vessels and the anatomical localisation
of the stenosis. Thus our data suggested that the Asp298 variant
of eNOS could contribute to the generalised architecture of the
vessels. This hypothesis is supported by in vivo evidence that
eNOS mutant mice display a paradoxical increase in wall
thickness accompanied by a hyperplastic response of the arte-
rial wall after carotid artery ligation.24 This suggests that a pri-
mary defect in the NOS/NO pathway may promote abnormal
remodelling and pathological changes in vessel wall morphol-
ogy associated with atherosclerosis. Thus it is possible that in
the process of atherosclerotic remodelling of adult human
vessels, alterations in NO production resulting from the
substitution of Glu298 with Asp298 could have a major impact on
smooth muscle cell migration and proliferation. Indeed,
despite the apparently conservative nature of the Glu!Asp
amino acid substitution, there is evidence that a similar
substitution in other enzymes can alter protein function.25
Recently, Philip and colleagues showed that enhanced vascu-
lar responsiveness to phenylephrine was associated with the
Asp298 allele,26 and a significant reduction in endothelium
dependent dilatation has been correlated with Glu298!Asp
polymorphism in early pregnancy.27 On the other hand, a
study by Schneider and associates appeared to exclude an
effect of eNOS Glu298!Asp polymorphism on endothelium
dependent vasodilatation.28 Furthermore, Sofowora and col-
leagues reported that Asp298 homozygotes excreted signifi-
cantly less nitrate/nitrite than Glu298 homozygotes without
affecting nitric oxide mediated vascular responses.29 Thus the
impact of Glu298!Asp polymorphism on endothelial NO func-
tion remains to be clarified.
Finally, genetic contributions of eNOS to plasma NO
metabolite concentrations have been recently reported. The
mutant allele of the T786!C polymorphism in the promoter
region of the eNOS gene has been associated with a reduced
promoter activity and endothelial synthesis of NO, both of
which predispose to coronary spasm in the Japanese
population.30 Moreover, Yoshimura and colleagues found that
the T786!C variant is in linkage disequilibrium with the eNOS
gene intron 4b/a polymorphism,31 which is also reported to be
involved in smoking dependent coronary artery disease,32 sug-
gesting that the T786!C mutation underlies the functional
characteristics of the intron 4a allele. It is not known whether
the associations that we reported in this study reflect a hypo-
functional enzyme or linkage disequilibrium between the
Glu298!Asp polymorphism and another functional variant
within the eNOS gene or another gene.
Conclusions
We observed that the Glu298!Asp polymorphism of the eNOS
gene is associated with the presence, extent, and severity of
angiographically assessed coronary artery disease in the Ital-
ian population. Because this polymorphism has also recently
been associated with carotid atheroma in the same popula-
tion, more studies are needed to investigate whether the
Glu298!Asp polymorphism of the eNOS could represent an
useful genetic marker to identify individuals prone to the
development of atherosclerotic diseases.
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